Global preventive AIDS vaccine R&D investment totaled US$818 million in 2013, with the public sector providing US$666 million (81%), the philanthropic sector providing US$121 million (15%), and the commercial sector contributing US$31 million (4%). The 2013 total investment represents a decrease of US$29 million (4%) below global preventive AIDS vaccine R&D investment in 2012.
Thanks to significant recent progress in HIV vaccine research and development, scientists are increasingly confident that HIV vaccines will someday become available for general use. The only question is when that will happen. Getting there will require both sustained support for global HIV vaccine R&D and a policy environment that continues to encourage and enable such efforts. Cognizent of those needs, IAVI and its partners strive to:
- Contribute to the evidence base demonstrating the potential value and impact of HIV vaccines and other new HIV prevention technologies, and the research required to develop these tools.
- Create a more supportive policy environment for HIV vaccine R&D at the global, regional, and national levels—one that encourages innovation, collaboration, and a sustained commitment of resources to all such efforts. IAVI seeks to accomplish this in a variety of ways, including its participation in the HIV Vaccines and Microbicides Resource Tracking Working Group.
To achieve these goals, IAVI works in concert with its advocacy and technical partners, including AVAC: Global Advocacy for HIV Prevention, the Futures Institute, the Global Health Technologies Coalition, the International Partnership for Microbicides and theJoint United Nations Programme on HIV/AIDS (UNAIDS).
IAVI and the Futures Institute, with support from the U.S. Agency for International Development (USAID), have developed a model to estimate the impact that preventive AIDS vaccines could have on HIV epidemics at both national and global levels. Such projections can assist policymakers, vaccine developers, advocates and funders make informed decisions and effective resource allocations. Such modeling has shown that a vaccine could avert millions of new HIV infections and AIDS-related deaths, and will be needed to end AIDS even if ambitious targets for access to HIV prevention, treatment and care are reached before a vaccine is introduced.